Pharmacokinetics of xylazine and fentanyl in patients presenting to the emergency department after non-fatal opioid overdose
Top Cited Papers
- 3 June 2026
- journal article
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 285, 113228
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Health and Human Services
- University of Massachusetts Medical School
- Intramural Research Program (ZIA DA000523)
- Intramural Research Program (DA056892)
- National Institutes of Health
- National Institute on Drug Abuse
This publication has 36 references indexed in Scilit:
- Local Anesthetics Adulterating the Illicit Fentanyl SupplyJAMA Psychiatry, 2025
- Tranq burn: Exploring the etiology of xylazine-related soft tissue injuriesInternational Journal of Drug Policy, 2025
- Medetomidine Infiltrates the US Illicit Opioid MarketJAMA, 2024
- Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats.Experimental and Clinical Psychopharmacology, 2024
- Xylazine poisoning: a systematic reviewClinical Toxicology, 2022
- Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisisDrug and Alcohol Dependence, 2022
- Heroin uncertainties: Exploring users’ perceptions of fentanyl-adulterated and -substituted ‘heroin’International Journal of Drug Policy, 2017
- Clinical Pharmacokinetics and Pharmacodynamics of DexmedetomidineClinical Pharmacokinetics, 2017
- Mechanism of hyperglycemia induced by extensive wounds and generalized surgical infectionActa Diabetologica, 1987
- Intravenous fentanyl kineticsClinical Pharmacology & Therapeutics, 1980